Basiliximab pharmacokinetics

Pharmacodynamics and Pharmacokinetics of mAbs Muromonab CD-3 Pharmacokinetics Basiliximab Pharmacokinetics Trastuzumab Pharmacokinetics Infliximab Pharmacokinetics Rituximab Pharmacokinetics Palivizumab Pharmacokinetics Recommendations for Future Study References... 

Pharmacokinetics Complete and consistent blocking of the IL-2 receptor is maintained as long as serum basiliximab levels exceed 0.2pg/ml. As concentrations fall below this level, expression of IL-2 receptor returns to pre-therapy values within 1-2 weeks. Basiliximab has a steady-state volume of distribution of 9 liters and total body clearance of 41 ml/h. Its elimination half-life ranges from 7 to 10 days. There is a dose-proportional increase in peak concentration (Cmax) and area under the curve (AUC) up to the highest tested single dose of 60 mg. No clinically relevant influence of body weight or gender on distribution volume or clearance has been observed in adult patients. Elimination... 

Various methods are available to estimate population parameters, but today the nonlinear mixed effects modeling approach is the most common one employed. Population analyses have been performed for mAbs such as basiliximab, daclizu-mab and trastuzumab, as well as several others in development, including clenolixi-mab and sibrotuzumab. Population pharmacokinetic models comprise three submodels the structural the statistical and covariate submodels (Fig. 3.13). Their development and impact for mAbs will be discussed in the following section. 

Kovarki J M, Kahan B D, Rajagopalan P R, et al. (1999). Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. Transplant. 68 1288-1294. 

Kovarki J M, Nashan B, Neuhaus P, et al. (2001). A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin. Pharmacol. Ther. 69 201-209. 

---